A股异动 | 青松股份涨停 购口罩生产设备部分已可正常生产
格隆汇2月6日丨青松股份(300132.SZ)涨停,报13.63元,暂成交5814万元,最新总市值70.4亿。公司昨日公告称,控股子公司诺斯贝尔于近日采购了医用口罩生产设备,目前已向中山市市场监督管理局申请并取得《中山市突发公共卫生事件一级响应期间应急医疗器械生产备案凭证》。此次采购设备共5台,每台设备的医用口罩生产能力为每日4万只,目前已有1台设备安装调试完毕,可正常生产医用口罩。余下设备将陆续运抵诺斯贝尔工厂并进行安装调试。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.